biostudies-literatureUnknown12(9)Wei XRecurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) is a marker of poor prognosis. However, the reliable biomarkers of post-LT HCC recurrence remain to be identified. In this study, serial peripheral blood samples from the LT recipients with and without HCC recurrence were collected at five time points. Single-cell mass cytomertry (CyTOF) was utilized for the in-depth analysis of peripheral blood monocellular cells (PBMCs). CyTOF analysis showed that at 3 weeks post-LT, the activated immune cell population was increased, while the fraction of immune cells with suppressive functions (myeloid-derived suppressive cells) was reduced. The post-LT immune composition in patients with LT for HCC was enormously different from that in patients with LT for causes other than American journal of cancer research4160-4176https://www.ebi.ac.uk/biostudies/studies/S-EPMC9548010biostudies-literaturePrediction of tumor recurrence by distinct immunoprofiles in liver transplant patients based on mass cytometry.PMC9548010Xie WYin WLi CYang MZheng SLu DWei XPan BZeng XWang KYang FCen BFan GKhan ARSu RShu WXie HChen WPan LZhuang LXu XfalsePrediction of tumor recurrence by distinct immunoprofiles in liver transplant patients based on mass cytometry.Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) is a marker of poor prognosis. However, the reliable biomarkers of post-LT HCC recurrence remain to be identified. In this study, serial peripheral blood samples from the LT recipients with and without HCC recurrence were collected at five time points. Single-cell mass cytomertry (CyTOF) was utilized for the in-depth analysis of peripheral blood monocellular cells (PBMCs). CyTOF analysis showed that at 3 weeks post-LT, the activated immune cell population was increased, while the fraction of immune cells with suppressive functions (myeloid-derived suppressive cells) was reduced. The post-LT immune composition in patients with LT for HCC was enormously different from that in patients with LT for causes other than 2022-01-01T00:00:00Z20222025-04-05T12:18:51.184Z2025-04-05T12:18:51.184ZS-EPMC954801036225628